A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of EDG-7500 in Participants With Impaired and Normal Hepatic Function
Latest Information Update: 12 Mar 2026
At a glance
- Drugs EDG-7500 (Primary)
- Indications Kidney disorders
- Focus Pharmacokinetics
- Sponsors Edgewise Therapeutics
Most Recent Events
- 09 Mar 2026 Status changed from not yet recruiting to recruiting.
- 16 Jan 2026 New trial record